Please use this identifier to cite or link to this item: 10.1080/14760584.2019.1573145
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMészner, Zsófia-
dc.contributor.authorWysocki, Jacek-
dc.contributor.authorRichter, Darko-
dc.contributor.authorZavadska, Dace-
dc.contributor.authorIvaskeviciene, Inga-
dc.contributor.authorUsonis, Vytautas-
dc.contributor.authorPokorn, Marko-
dc.contributor.authorMangarov, Atanas-
dc.contributor.authorJancoriene, Ligita-
dc.contributor.authorMan, Sorin C.-
dc.contributor.authorKristufkova, Zuzana-
dc.contributor.authorJesenak, Milos-
dc.contributor.authorTešović, Goran-
dc.contributor.authorPluta, Justyna-
dc.contributor.authorWolfson, Lara J.-
dc.date.accessioned2021-04-27T08:40:01Z-
dc.date.available2021-04-27T08:40:01Z-
dc.date.issued2019-03-04-
dc.identifier.citationMészner , Z , Wysocki , J , Richter , D , Zavadska , D , Ivaskeviciene , I , Usonis , V , Pokorn , M , Mangarov , A , Jancoriene , L , Man , S C , Kristufkova , Z , Jesenak , M , Tešović , G , Pluta , J & Wolfson , L J 2019 , ' Burden of varicella in Central and Eastern Europe : findings from a systematic literature review ' , Expert Review of Vaccines , vol. 18 , no. 3 , pp. 281-293 . https://doi.org/10.1080/14760584.2019.1573145-
dc.identifier.issn1476-0584-
dc.identifier.urihttps://dspace.rsu.lv/jspui/handle/123456789/3936-
dc.descriptionFunding Information: The authors take full responsibility for the scope, direction, and content of the manuscript, and have approved the submitted manuscript. Medical writing assistance was provided by Eleanor Finn of PAREXEL International and was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. The authors wish to thank the following for contributions in development of the manuscript: Barbara J. Kuter, PhD, MPH, Global Vaccines Medical Affairs, and Tracey J. Weiss, Center for Observational and Real-World Evidence (CORE), Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Funding Information: The study was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Funding Information: J. Wysocki received travel grants to attend international scientific conferences and fees for lectures from Pfizer and payment from a grant sponsored by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. I. Ivaskeviciene has received a USA travel grant to attend international scientific meeting, from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth. M. Pokorn has received a research grant from Pfizer and payment for lectures from Pfizer, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA and GSK. L. Jancoriene has received travel grants to attend international scientific conferences and fees for lectures from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, AbbVie and Pfizer and payment for a clinical study sponsored by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. J. Pluta and L.J. Wolfson are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and stockholders of Merck & Co., Inc., Kenilworth, NJ, USA. Publisher Copyright: © 2019, © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.-
dc.description.abstractIntroduction: Vaccination against varicella rapidly reduces disease incidence, resulting in reductions in both individual burden and societal costs. Despite these benefits, there is no standardization of varicella immunization policies in Europe, including countries in Central and Eastern Europe (CEE). Areas covered: This systematic literature review identified publications on the epidemiology of varicella, its associated health and economic burden, and vaccination strategies within the CEE region, defined as Albania, Bosnia-Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Serbia, Slovakia, and Slovenia. Twenty-six studies were identified from a search of PubMed, Embase®, and MEDLINE® biomedical literature databases, supplemented by gray literature and country-specific/global websites. Expert commentary: Limited information exists in published studies on the burden of varicella in CEE. The wide variability in incidence rates between countries is likely explained by a lack of consistency in reporting systems. Funded universal varicella vaccination (UVV) in CEE is currently available only in Latvia as a one-dose schedule, but Hungary together with Latvia are introducing a two-dose strategy in 2019. For countries that do not provide UVV, introduction of vaccination is predicted to provide substantial reductions in cases and rates of associated complications, with important economic benefits.en
dc.format.extent13-
dc.format.extent2163929-
dc.language.isoeng-
dc.relation.ispartofExpert Review of Vaccines-
dc.rightsinfo:eu-repo/semantics/openAccess-
dc.subjectBurden of illness-
dc.subjectCentral and Eastern Europe-
dc.subjectsystematic literature review-
dc.subjectvaccination-
dc.subjectvaricella-
dc.subject3.1 Basic medicine-
dc.subject1.1. Scientific article indexed in Web of Science and/or Scopus database-
dc.subjectImmunology-
dc.subjectMolecular Medicine-
dc.subjectPharmacology-
dc.subjectDrug Discovery-
dc.subjectSDG 3 - Good Health and Well-being-
dc.titleBurden of varicella in Central and Eastern Europe : findings from a systematic literature reviewen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/systematicreview-
dc.identifier.doi10.1080/14760584.2019.1573145-
dc.contributor.institutionDepartment of Paediatrics-
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85063521488&partnerID=8YFLogxK-
dc.description.statusPeer reviewed-
Appears in Collections:Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure

Files in This Item:


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.